Notice of Pre-AIA or AIA Status
The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA .
Upon further consideration previously presented restriction requirement is withdrawn.
Claims 1-20 are pending and are examined together.
See interview summary 03/04/2026.
Claim Rejections - 35 USC § 102
The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:
A person shall be entitled to a patent unless –
(a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention.
Claim(s) 1-20 are rejected under 35 U.S.C. 102((a)(1) as being anticipated by Sulaiman, New J. Chem., 2022, 46, 16821–1683.
Sulaiman teaches method of making the claimed compounds at page 16824, bottom of column B corresponding to instant claim 13.
Sulaiman teaches x-ray diffraction pattern of the compounds having the limitations of claims 4.
Sulaiman teaches chemical stability of the claimed compounds at page 168289, column A corresponding to claim 12.
Sulaiman teaches HCT116 & MCF-7 cell line at page 16826 bottom of column B corresponding to claims 5, 9 & 6, 6, 10, 11 and 15.
The teaching of includes), cell proliferation assay data corresponding to method of treatment of cancer corresponding to claims 13-19 and by virtue of commonsense claim 19.
Claim Rejections - 35 USC § 112
The following is a quotation of 35 U.S.C. 112(b):
(b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention.
The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph:
The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.
Claims 2 and 8 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject
to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention.
These claims dependent claim 1 and are drawn to an amine containing ligand that lacks antecedent basis.
The art made of record and not relied upon is considered pertinent to applicant's disclosure.
Part of continued teachings of Iranian Nuclear Medicine, Mohammadi, Iran Journal of Organometallic Chemistry (2023), 996, 122759, on dinuclear Pt complexes for cancer. Reviews on dinuclear Pt complexes for cancer, see Lukovic, Int. J.Mol.Sci. 2023, 25, 8525.
Review on Au complexes for cancer, see Begum, Nature-Inspired Gold(I) Complexes as Anticancer Agents: Ligand Design, Structure–Activity Relationships, and Mechanisms, Cancers 2026, 18, 631, 1-20.
Any inquiry concerning this communication or earlier communications from the examiner should be directed to NIZAL S CHANDRAKUMAR whose telephone number is (571)272-6202. The examiner can normally be reached M-F 8-5 EST.
Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice.
If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Andrew Kosar can be reached at (571) 272-0913. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.
Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.
/NIZAL S CHANDRAKUMAR/Primary Examiner, Art Unit 1625
Prosecution Insights